EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses

• Main Authors: Dinoop Ravindran Menon (Author), Yang Li (Author), Takeshi Yamauchi (Author), Douglas Grant Osborne (Author), Prasanna Kumar Vaddi (Author), Michael F Wempe (Author), Zili Zhai (Author), Mayumi Fujita (Author)
• 格式: 圖書
• 出版: MDPI AG, 2021-10-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Over the last decade, therapies targeting immune checkpoints, such as programmed death-1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response rates and immune-related adverse events remain a major concern. Here, we report that epigallocatechin gallate (EGCG), the most...